Comparative Effects of Vivax Malaria, Fever and Diarrhoea on Child Growth
Overview
Authors
Affiliations
Background: The adverse impact of Plasmodium vivax on child health beyond acute febrile illness is poorly studied. The effect of vivax malaria on child growth was evaluated and compared with diarrhoeal disease and non-specific fever.
Methods: Using data from a 43-month longitudinal cohort of children 0-72 months of age (n = 442) in the Peruvian Amazon, ponderal and linear growth velocities over 2-, 4- and 6-month periods were examined using longitudinal models and related to the incidence of disease during the same period.
Results: An episode of vivax malaria led to 138.6 g (95% confidence interval (CI) 81.9-195.4), 108.6 g (62.8-153.2) and 61 g (20.9-101.1) less weight gain over 2-, 4- and 6-month intervals, respectively. These deficits were larger than both diarrhoea (21.9, 17.2 and 13.8 g less weight gain, respectively) and fever (39.0, 30.3 and 25.6 g less weight gain, respectively). An incident episode of vivax also led to 0.070 cm (0.004-0.137) and 0.083 cm (0.015-0.151) less linear growth over 4 and 6 months, respectively, which were also larger than deficits from diarrhoea (0.029 and 0.028 cm, respectively) and fever (not associated with linear growth deficits). Despite the larger effect of P. vivax incident episodes on growth of a particular child, diarrhoeal disease had a larger cumulative impact on growth deficits as diarrhoeal incidence rates in this community are >10-fold higher than vivax malaria.
Conclusions: Disease control measures for vivax malaria and diarrhoeal disease have the potential to improve the growth of children in endemic areas.
Schiaffino F, Colston J, Paredes Olortegui M, Penataro Yori P, Mourkas E, Pascoe B EClinicalMedicine. 2024; 76:102841.
PMID: 39380966 PMC: 11460251. DOI: 10.1016/j.eclinm.2024.102841.
Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
Sharma R, Sharma H, Jones S, Borghini-Fuhrer I, Domingo G, Gibson R Malar J. 2024; 23(1):145.
PMID: 38741094 PMC: 11092214. DOI: 10.1186/s12936-024-04924-z.
Gelaw N, Tessema G, Gelaye K, Tessema Z, Ferede T, Tewelde A PLoS One. 2022; 17(12):e0277565.
PMID: 36584143 PMC: 9803186. DOI: 10.1371/journal.pone.0277565.
Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review.
Drysdale M, Tan L, Martin A, Fuhrer I, Duparc S, Sharma H Infect Dis Ther. 2022; 12(1):33-51.
PMID: 36378465 PMC: 9868225. DOI: 10.1007/s40121-022-00713-w.
Donkor W, Mbai J, Sesay F, Ali S, Woodruff B, Hussein S BMC Public Health. 2022; 22(1):264.
PMID: 35139826 PMC: 8827289. DOI: 10.1186/s12889-021-12439-4.